Core Scientific reported capital expenditure of $729M for fiscal 2025, +667.7% versus $95M in fiscal 2024.
Capex equals 229% of fiscal-year revenue ($319M).
The highest single reported period was $389M (period ending 2026-03-31).
The latest reported period, 6 months to 2026-06-30, shows $954M; the dataset covers 23 reported periods (2020–2026), all from SEC XBRL filings.
Every capital-expenditure figure Core Scientific has reported to the SEC, unedited. Capex is the XBRL concept PaymentsToAcquirePropertyPlantAndEquipment; a capex/revenue ratio above 100% means the company is investing more than it earns to secure capacity. Each row links to the filing it came from.
| Fiscal year | Capex | YoY |
|---|---|---|
| FY2025 | $729M | +668% |
| FY2024 | $95M | +488% |
| FY2023 | $16M | -96% |
| FY2022 | $384M | — |
| FY2021 | $0 | — |
| FY2020 | $0 | — |
| Period end | Period | Capex |
|---|---|---|
| 2026-06-30 | FY2026 6 mo. cumulative | $954M |
| 2026-03-31 | FY2026 Q1 | $389M |
| 2025-12-31 | FY2025 FY | $729M |
| 2025-09-30 | FY2025 9 mo. cumulative | $454M |
| 2025-06-30 | FY2025 6 mo. cumulative | $210M |
| 2025-03-31 | FY2025 Q1 | $88M |
| 2024-12-31 | FY2024 FY | $95M |
| 2024-09-30 | FY2024 9 mo. cumulative | $66M |
| 2024-06-30 | FY2024 6 mo. cumulative | $35M |
| 2024-03-31 | FY2024 Q1 | $32M |
| 2023-12-31 | FY2023 FY | $16M |
| 2023-09-30 | FY2023 9 mo. cumulative | $5M |
| 2023-06-30 | FY2023 6 mo. cumulative | $2M |
| 2023-03-31 | FY2023 Q1 | $2M |
| 2022-12-31 | FY2022 FY | $384M |
| 2022-09-30 | FY2022 9 mo. cumulative | $244M |
| 2022-06-30 | FY2022 6 mo. cumulative | $239M |
| 2022-03-31 | FY2022 Q1 | $133M |
| 2021-12-31 | FY2021 FY | $0 |
| 2021-09-30 | FY2021 9 mo. cumulative | $116M |
| 2021-06-30 | FY2021 6 mo. cumulative | $39M |
| 2021-03-31 | FY2021 Q1 | $11M |
| 2020-12-31 | FY2020 FY | $0 |
Source: SEC XBRL company-concept API, concept PaymentsToAcquirePropertyPlantAndEquipment, CIK 1839341. See Methodology.